Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal

benzinga.com/general/biotech/25/05/45504107/genetic-data-from-23andme-ends-up-with-this-company-in-256-million-deal

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced Monday that it has secured the winning bid in the bankruptcy auction for key assets of 23andMe Holding Co. in a $256 million deal to boost its genetics-based drug discovery efforts.
The acquisition includes 23andMe’s Personal Genome…

This story appeared on benzinga.com, 2025-05-19 19:29:24.
The Entire Business World on a Single Page. Free to Use →